Pediatric cancer women survivors
OtherWomen will incur a blood taking to obtain fertility indication.
NCT Number: NCT02665819
PanCareLIFE Study is a cohort study of patients treated for cancer in childhood, and biological case-control study nested in the cohort (WP4) is coordinated by Erasmus MC-Sophia Children's Hospital in Holland.
Ensure optimal patient quality of life throughout his life is a priority for the research teams. PanCareLIFE Study also aims to identify the factors that predispose to impaired quality of life. It is in this light that will be offered to patients a quality of life questionnaires during the period of treatment and then periodically during long-term follow-up.
Looking for future studies?
Notify Me18 year and older
Female
Observational
Chu Grenoble, Grenoble, France
PanCareLIFE Study is a cohort study of patients treated for cancer in childhood, and biological case-control study nested in the cohort (WP4) is coordinated by Erasmus MC-Sophia Children's Hospital in Holland. At European level, approximately 1,200 women are expected in this latest study, the patients were already identified through certain regional or national registries in terms of cumulative doses of chemotherapy, surgery, radiation.
Ensure optimal patient quality of life throughout his life is a priority for the research teams. PanCareLIFE Study also aims to identify the factors that predispose to impaired quality of life. It is in this light that will be offered to former patients to complete quality of life questionnaires during the period of treatment and then periodically during long-term follow-up.
The SALTO-BIO study is the French part of the European study PanCareLIFE. CHU of Saint-Etienne as French promotor, will organize this study only on the Rhône-Alpes region (Lyon, Grenoble and Saint-Etienne centers) and will participate as co-investigator and "data provider "to WP2, WP3, WP4 and WP6. Indeed, ototoxicity is already studied by a French group.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Women will incur a blood taking to obtain fertility indication.
Time frame: Day 1
In this arm women will incur a blood taking to measure the FSH hormone rate.
Time frame: Day 1
In this arm women will incur a blood taking to measure the AMH hormone rate.
Time frame: Day 1
With the blood taking realized for each patient, genetic markers will be obtained to identify their fertility capacity.
Time frame: Day 1
The quality of life for each patient will be measured with the SF-36 scale.
Time frame: Day 1
With a pan-genomic method, new loci (associated to ovarian toxicity) will be identified.
Centre Hospitalier Universitaire de Saint Etienne
Other
SALTO-BIO (Long Term Follow up in Oncology) - PanCareLIFE. Long Term Support for Pediatric Cancer Survivors in Rhône-Alpes. Evaluation of Women Fertility.
Acronym: SALTO-BIO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05507736
Diarrhea, Neoplasms
Esplugues de Llobregat, Barcelona, Spain
View Trial DetailsNCT07667712
Neoplasms, Neurologic Manifestations
Kocaeli, İzmit, Turkey (Türkiye)
View Trial DetailsNCT04479514
CNS Tumor, Childhood, Central Nervous System Neoplasms
Boston, Massachusetts, United States
View Trial DetailsNCT05872893
Neoplasms, Pediatric Cancer
Yerevan, Armenia
View Trial Details